Clinical Trial Update: Novel Autologou CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma [Phase 2]

View source ↗

Summary

This entry provides an update on a Phase 2 clinical trial of a novel autologous CAR-T therapy for relapsed/refractory B-cell lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Lymphoma

Drugs mentioned

• Novel Autologous CAR-T Therapy

Snippet

Sponsor: First Affiliated Hospital of Zhejiang University | Conditions: B Cell Lymphoma | Phase 2 | Status: UNKNOWN